Free Trial

Genflow Biosciences (GENF) Competitors

GBX 1.85 -0.15 (-7.60%)
As of 10:54 AM Eastern

GENF vs. SBTX, COS, APTA, C4XD, DDDD, AREC, SAR, POLB, OKYO, and AOR

Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), Aptamer Group (APTA), C4X Discovery (C4XD), 4D pharma (DDDD), Arecor Therapeutics (AREC), Sareum (SAR), Poolbeg Pharma (POLB), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.

Genflow Biosciences vs. Its Competitors

Genflow Biosciences (LON:GENF) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Genflow Biosciences has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.01-368.13
SkinBioTherapeutics£2.68M13.67-£3.71M-£0.01-1,131.60

In the previous week, Genflow Biosciences had 3 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 3 mentions for Genflow Biosciences and 0 mentions for SkinBioTherapeutics. Genflow Biosciences' average media sentiment score of 0.27 beat SkinBioTherapeutics' score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
SkinBioTherapeutics Neutral

2.7% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 3.4% of SkinBioTherapeutics shares are owned by institutional investors. 42.8% of Genflow Biosciences shares are owned by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genflow Biosciences has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Genflow Biosciences has a net margin of 778.46% compared to SkinBioTherapeutics' net margin of -237.95%. SkinBioTherapeutics' return on equity of -115.86% beat Genflow Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences778.46% -208.12% -58.66%
SkinBioTherapeutics -237.95%-115.86%-61.18%

Summary

Genflow Biosciences beats SkinBioTherapeutics on 9 of the 12 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

MetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£8.38M£225.85M£6.03B£2.59B
Dividend YieldN/A3.81%5.73%5.32%
P/E Ratio-368.1399.1085.144,370.21
Price / SalesN/A5,788.72593.69100,931.49
Price / Cash3.0013.1925.7727.90
Price / Book7.45100.2912.337.74
Net Income-£1.76M-£90.99M£3.32B£5.89B
7 Day Performance63.11%-0.16%-0.38%0.03%
1 Month Performance111.20%4.60%8.34%1.84%
1 Year Performance-5.23%675.16%73.00%136.30%

Genflow Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 1.85
-7.6%
N/A-4.8%£8.38MN/A-368.135Gap Down
High Trading Volume
SBTX
SkinBioTherapeutics
N/AGBX 14.80
+2.1%
N/A+14.2%£37.52M£2.68M-1,184.0011Gap Up
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01M-8.283,350
APTA
Aptamer Group
N/AGBX 1.01
-10.2%
N/A+371.4%£30.34M£1.22M-360.7137Earnings Report
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049High Trading Volume
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718K-1.08106
AREC
Arecor Therapeutics
N/AGBX 78
+0.6%
N/A+11.6%£29.26M£5.06M-339.1310
SAR
Sareum
N/AGBX 15.98
-19.7%
N/A-44.8%£27.47MN/A-614.623,211Gap Down
High Trading Volume
POLB
Poolbeg Pharma
N/AGBX 3.70
+4.2%
N/A-55.0%£24.75MN/A-324.5612
OKYO
OKYO Pharma
N/AN/AN/AN/A£23.24MN/A-140.007Gap Down
AOR
AorTech International
N/AN/AN/AN/A£19.99M£539K-33.383

Related Companies and Tools


This page (LON:GENF) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners